Recently, new immune-based treatments have shown impressive results when multiple myeloma returns, changing how doctors treat patients early after relapse.
Should we use AI to pre-screen whether people can see a human therapist? And should we use AI to do initial intervention?
BTK inhibitors (BTKi) in mantle cell lymphoma (MCL) are examined by Tycel J. Phillips, MD, particularly as potential first-line therapy.
With Enhertu and Datroway, Daiichi Sankyo has made itself a top-tier player in antibody-drug conjugates. | With Enhertu and Datroway, Daiichi Sankyo has made itself a top-tier player in antibody-drug ...
In patients with clear cell renal cell carcinoma (ccRCC), there are a number of second-line options to consider. Sumanta K. Pal, MD, FASCO, professor, Department of Medical Oncology & Therapeutics ...
Onvansertib combined with FOLFIRI and Avastin shows dose-dependent improvements in tumor response and disease control for RAS ...
Targeted therapies, including BTK inhibitors and venetoclax, have replaced chemoimmunotherapy as the first-line standard for CLL, emphasizing patient preference and risk factors in treatment decisions ...
Children and teens often express what they feel through behavior long before they can explain it. Big emotions like anxiety, anger, or sadness might show up as acting out, withdrawal, or changes in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results